Bio-Path Has Initiated A Therapeutic Program To Develop BP1001-A For Obesity And Related Metabolic Diseases, This Program Marks The First Application Of DNAbilize Technology For Development Of A Non-cancer Application
Bio-Path Has Initiated A Therapeutic Program To Develop BP1001-A For Obesity And Related Metabolic Diseases, This Program Marks The First Application Of DNAbilize Technology For Development Of A Non-cancer Application
Bio-Path已啓動治療項目,開發BP1001-A用於肥胖和相關代謝性疾病,該項目標誌着DNAbilize技術首次應用於非癌症應用的開發。
Bio-Path Has Initiated A Therapeutic Program To Develop BP1001-A For Obesity And Related Metabolic Diseases, This Program Marks The First Application Of DNAbilize Technology For Development Of A Non-cancer Application
Bio-Path已啓動治療項目,開發BP1001-A用於肥胖和相關代謝性疾病,該項目標誌着DNAbilize技術首次應用於非癌症應用的開發。